In the TRAIN‐2 and BERENICE studies, neoadjuvant chemotherapy combined with trastuzumab and pertuzumab resulted in a tpCR rate of 51.2%–57.3% in patients with HR‐positive, HER2‐positive early or locally advanced breast cancer, which might be attributed to longer neoadjuvant therapy course (20–24 weeks in BERENICE and 27 weeks in TRAIN‐2).31, 32. The gene discussed is ERBB2; the disease is breast cancer.